FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 404 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Our sun safety messaging tours the UK with the NIVEA Sun... August 9, 2021 Doing More—Together—to End Cancer as We Know It February 9, 2023 How Sharing My Story Helps Me Cope With an Advanced Brain... April 15, 2021 Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients... February 24, 2026 Load more HOT NEWS New obesity strategy is a ‘landmark day for the nation’s health’... Skin cancer death rates in men risen dramatically in the last... Scientists Find Genetic Changes Linked to Cancer in Children Mom Diagnosed With Breast Cancer Adopts Healthy Lifestyle To Reinvent Her...
